Fluicell AB

As of June 30, 2026, Fluicell AB carries a market capitalization of 41.49M, placing it among publicly traded companies globally. Its enterprise value stands at 43.46M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Fluicell AB's next confirmed earnings release is scheduled for November 13, 2026.

As of June 30, 2026, Fluicell AB has 1.37M shares outstanding.

As of June 30, 2026, Fluicell AB trades at a trailing price-to-earnings ratio of 14.82. The price-to-sales ratio is 2.25, and the price-to-book ratio stands at 2.52.

As of June 30, 2026, Fluicell AB trades at an EV/EBITDA multiple of 14.77 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.36 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 16.69 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 43.46M versus a market cap of 41.49M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Fluicell AB maintains a current ratio of 1.40, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 12.14, indicating elevated leverage, while an interest coverage ratio of 20.15 demonstrates strong ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Fluicell AB posted a return on equity (ROE) of 18.57, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 15.38 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 12.76, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 18.32, useful for judging operating efficiency across full business cycles. The company generates approximately 1.64M in revenue per employee across its workforce of 11.25, a quick read on workforce productivity versus industry peers. Inventory turnover of -1.69 indicates how many times Fluicell AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on October 22, 2026, Fluicell AB's stock has gained approximately 103.85% over the past 52 weeks. The 50-day moving average sits at 30.36, while the 200-day moving average is 24.23.

Over the twelve months ended June 30, 2026, Fluicell AB generated 18.44M in revenue and converted that into 2.80M in net income, yielding earnings per share of 2.04. EBITDA reached 2.94M, while operating income came in at 2.60M.

As of June 30, 2026, Fluicell AB holds 30,000.00 in cash and equivalents against 2.00M in total debt, resulting in a net debt position of 1.97M. Total book value stands at 16.47M, with working capital of 3.44M providing operational flexibility.

Fluicell AB produced -167,000.00 in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Fluicell AB posted a gross margin of 126.70, reflecting its pricing power and cost economics. The operating margin of 14.12 and net profit margin of 15.18 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -0.40: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -4.82, meaning Fluicell AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Fluicell AB's most recent stock split took place on March 26, 2025 with a 350:1 split ratio.

As of June 30, 2026, Fluicell AB has an Altman Z-Score of -9.88, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.